News | Nuclear Imaging | November 16, 2015

GE Features Latest Molecular Imaging Technology at RSNA 2015

Discovery IQ with Q.Clear technology and Discovery NM/CT 670 Pro with Q.Suite for SPECT/CT imaging highlight offerings

GE Healthcare, molecular imaging, PET/CT, Discovery IQ, Discovery NM/CT 670 Pro, RSNA 2015

Discovery IQ PET/CT image courtesy of GE Healthcare

November 16, 2015 — GE Healthcare’s Molecular Imaging business will showcase the Discovery IQ positron emission tomography/computed tomography (PET/CT) platform at this year’s Radiological Society of North America (RSNA) annual meeting, delivering both outstanding image quality and intelligent quantitation. According to the company, Discovery IQ delivers the highest NEMA (National Electrical Manufacturers Association) sensitivity (up to 22 cps/kBq), the largest axial field-of-view (up to 26 cm) and the highest clinical NECR (Noise-Equivalent-Count-Rate) in the industry. Discovery IQ can image with both half the PET dose and half the scan time.

GE Healthcare’s new Q.Clear technology is a critical component of Discovery IQ. It delivers, for the first time, no trade-off between image quality and quantitative standardized uptake value (SUV) measurements. By providing two times improvement in both quantitative accuracy (SUVmean) and image quality (signal-to-noise ratio) in PET/CT imaging, this tool provides benefits to physicians across the cancer care continuum from diagnosis and staging disease to treatment planning and assessment.

GE will also be showcasing the Discovery NM/CT 670 Pro, which brings cutting-edge CT technology to nuclear medicine by now integrating with GE’s Optima CT540. It combines  50-slice equivalent CT speed for extended fast coverage of time-critical scans with advanced CT applications; dose management tools such as OptiDose, DoseWatch and ASiR; and a streamlined workflow for challenging stand-alone CT procedures.

Discovery NM/CT 670 Pro also features GE’s Q.Suite for single photon emission computed tomography (SPECT)/CT technologies. Two elements of Q.Suite for SPECT/CT are Q.AC and GE’s newest software innovation in nuclear medicine, Q.Metrix. Q.Metrix, a user-friendly application for measuring and reporting standard uptake values in the organ or lesion of interest, enables personalized, quantitative SPECT SUV results with multi-dimensional organ and lesion characterization. Q.AC is an image reconstruction technique designed to help improve accuracy of SPECT attenuation correction that enables quantitative SPECT measurements even at very low dose.

For more information: www.gehealthcare.com

Related Content

Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
News | Radiology Business | March 08, 2018
Scranton Gillette Communications’ Imaging Technology News (ITN) was recently named a 2018 Azbee Award finalist in five...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Enterprise imaging is evolving to address the problem — to find and assemble relevant information so that accurate diagnoses can be made efficiently and effectively
Feature | Enterprise Imaging | March 06, 2018 | By Jeff Zagoudis
Physicians are struggling with too much of a good thing. They have never had so much information about their patients....
Sponsored Content | Videos | Women's Health | February 27, 2018
Fujifilm details its latest innovations in women's health including its ASPIRE Cristalle mammography system with...
Sponsored Content | Videos | Pediatric Imaging | February 22, 2018
FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM SonoSite Inc., are offering a full-suite pediatric solutions...
Sponsored Content | Videos | Flat Panel Displays | February 21, 2018
This 5 megapixel, high-brightness color monitor has the high-definition display necessary for breast imaging.
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Overlay Init